Pub. Date : 2013 Mar
PMID : 30349613
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH) receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) concentrations in virtually every patients with acromegaly is possible. | pegvisomant | insulin like growth factor 1 | Homo sapiens |
| 2 | After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH) receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) concentrations in virtually every patients with acromegaly is possible. | pegvisomant | insulin like growth factor 1 | Homo sapiens |
| 3 | After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH) receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) concentrations in virtually every patients with acromegaly is possible. | pegvisomant | insulin like growth factor 1 | Homo sapiens |
| 4 | After the introduction of somatostatin analogs (LA-SMSA) and the growth hormone (GH) receptor antagonist, pegvisomant (Peg-v) normal serum insulin-like growth factor-1 (IGF-1) concentrations in virtually every patients with acromegaly is possible. | pegvisomant | insulin like growth factor 1 | Homo sapiens |
| 5 | Therefore high doses of Peg-v are necessary to control IGF-1. | pegvisomant | insulin like growth factor 1 | Homo sapiens |